+1 (502) 904-2126   One Westbrook Corporate Center, Suite 300, Westchester, IL 60154, USA   Site Map
ISSN: 2574 -1241

Impact Factor : 0.548

  Submit Manuscript

Review ArticleOpen Access

Optimized Ophthalmic: Advances in the Treatment of Ocular Diseases in Animals

Volume 1 - Issue 6

KR Kurup, PV Parikh*, JK Mahla and DA Ratnu

  • Author Information Open or Close
    • Department of Veterinary Surgery and Radiology, Anand Agricultural University, India

    *Corresponding author: Pineshkumar Parikh, Department of Veterinary Surgery and Radiology, College of Veterinary Science and Animal Husbandary, Anand Agricultural University (AAU), India

Received: October 26, 2017;   Published: November 06, 2017

DOI: 10.26717/BJSTR.2017.01.000500

Full Text PDF

To view the Full Article   Peer-reviewed Article PDF


The eye is a highly complex organ in terms of structure and function. It is a very sensitive organ, the function of which may be affected even with mild insult to its homeostasis, due to direct injury or due to other local or systemic diseases Scountzou [1]. The practice of ophthalmology, whether on humans or animals, can be reduced to the simple goal of getting the right pharmacological agent at the appropriate therapeutic dose to the target ocular tissue by a method that does not damage healthy tissue. In ocular disease, however, this simple goal becomes more challenging because of the highly sensitive ocular tissues (e.g., the uveal tract and retina) and the presence of tissue barriers to drug penetration, namely the lipophilic corneal epithelium, the hydrophilic corneal and sclera stroma, the conjunctival lymphatics, choroidal vasculature, and the blood-ocular barriers Weiner & Gilge [2].

Abbreviations: FDA: Food and Drug Administration; IOP: Intraocular Pressure; NSAIDS: Non Steroidal Anti-inflammatory Drugs; KCS: Kerato Conjunctivitis Sicca; AH: Aqueous Humor; CAIs: Carbonic Anhydrase inhibitors; PGAs: Prostaglandin F2α Analogues

Introduction| Drug Delivery System| Common Ocular Drugs| References|